Paramount Signs Away 2026. The Board Gets Ten New Deals.
On Friday afternoon, with an hour left in the trading day, Paramount filed a stipulation in federal court agreeing not to close the Warner deal until June 2027 at the latest — and the spread widened to 20% to pay you for the wait. Genco’s standoff did the opposite: the spread collapsed from 11% to 1% as the market priced a negotiated endgame. Allied Gold’s outside date — the binary we’ve tracked for a month — lands Wednesday. IMXI kept widening to 23% on politics, not process. And after two weeks of shrinkage, the tracker grew again: ten new deals joined this week, from Shell’s C$22B arrangement for ARC Resources to the Utz take-private at a 91% premium. Plus: a new feature on every deal page — What’s Changed — built for exactly the kind of week this was.
72
Active Deals
1.47%
Median Spread
~$833B
Total Value
2
Closed This Week
This Week’s Top Moves
$WBD20.3%
Paramount blinks: no closing until a merits ruling — or June 1, 2027
Last week the question was whether Paramount would wait out the lawyers. Friday it answered — in writing. In a court stipulation, Paramount agreed the merger “shall not close, be consummated, or otherwise be completed” until the earlier of five days after a merits determination in the state AG and WGA antitrust cases, or June 1, 2027 — the merger agreement’s expiration. The August 3 preliminary-injunction hearing is canceled; the WGA withdrew its motion. Paramount effectively conceded the timeline to get a full trial. Brussels cleared on Wednesday as expected; it no longer matters for timing.
The arb math changed shape, not sign. The 20% spread that was ~70% annualized to a Q3 close is now roughly 22–25% annualized to a spring-2027 resolution — and the ticking fee we’ve been flagging converts from threat to income: 25¢/share per quarter (~$650M) starting September 30, worth up to ~$0.75/share if the delay runs to June. The $7B break fee backstops abandonment. Next milestone is unglamorous but real: joint trial-scheduling statements due July 31. The states have proposed an April 2027 trial. This is now a litigation binary that pays you quarterly to hold it.
Wednesday. After a month of building, the binary finally lands
Still nothing from Beijing. The spread eased fractionally from last week’s 51.4% peak to 49.9%, which is noise, not information. What matters: the July 29 outside date is Wednesday, every approval outside China is complete, and the reported extension mechanism to September 29 — if both parties invoke it — is the difference between a checkpoint and a cliff. Three outcomes: NDRC clearance (the spread converts, spectacularly), a mutual extension (the binary rolls forward and the market decides how much hope to re-price), or termination rights come alive (the 30–35% downside case). Nobody outside the NDRC knows which. We’d simply repeat last week’s sizing line, because at 50% it’s still true: size it like the coin flip it is — and know that after Wednesday, you won’t have to.
The standoff collapses to a 1% spread — and out of the Risk/Reward ranking
The single biggest spread move of the week, and it went the other way: GNK collapsed from 11.2% to ~1.0% against the $27.34 indicative value (worth ~$27.06 with DSX at $2.26). The tender expired Friday at 5pm with the last disclosed count at 29.7% of the outside float — stalled, well short of a majority, against a board that re-rejected on July 13 and controls three of the four closing conditions. The market’s read: either a negotiated deal happens near current levels, or this drifts into stalemate — and at 1%, you’re not being paid for either branch.
We removed GNK from the Risk/Reward Top 6 this week for exactly that reason: with no signed agreement and no spread, it’s a contested-situation bet on board psychology, not an arb. It stays on the Contested tab, where the post-expiration count — and whether Diana extends, raises, files the long-promised F-4, or walks — is the next tell.
+3.6pp more — now it’s politics pricing the deal, and the facts haven’t moved
The widening continued: 19.2% to 22.8%, with the stock at ~$13 against $16.00. What changed is noise around the sole remaining gate — New York City politics entering the NYDFS conversation — not the approval count, which still reads 51 of 52 states plus every international clearance. Both companies reaffirmed in June. The outside date auto-extends August 10 to November 10. Our framing from three weeks ago stands, sharpened: if you believe the June recommitment, the odds-adjusted entry has only improved with the price; the ~45% break downside is the constant. WU’s Q2 call in the coming days is the single best read on buyer appetite you’ll get before the regulator speaks.
Two roll off — GSK collects Nuvalent, Public Storage completes NSA
Nuvalent closed July 15: GSK’s $124 tender finished with ~91.3% of shares in, the back-end 251(h) merger executed same-week, and the $10.6B deal delisted from Nasdaq — textbook two-step, announcement to completion in five weeks. National Storage Affiliates completed its merger into Public Storage. Both are archived with full spread histories. Between closings and additions, the tracker’s net count rose 68 → 72 — the first weekly expansion since June.
Added This Week — Ten New Deals
$ARX — ARC Resources → Shell — C$8.20 + 0.40247 SHEL (~C$32.80, ~C$22B) — H2 2026 $CRNX — Crinetics → Vertex — $85.00 cash (~$10B, 102% premium) — Q3 2026 $ESI — Element Solutions → Solstice — $10.00 + 0.5 SOLS (~$50.10, $14.5B) — 2027 $UTZ — Utz Brands → Intersnack — $14.25 cash (91% premium) — Q4 2026 $LXP — LXP Industrial → Brookfield / CPP — $61.20 cash ($5.2B) — Q4 2026 $DSGR — Distribution Solutions → LKCM — $35.00 take-private (79% owned) — Q4 2026 $TCBK — TriCo Bancshares → First Hawaiian — 2.095 FHB all-stock (~$2.0B) — Q4 2026 $BLFS — BioLife Solutions → Repligen — $11.25 + 0.1442 RGEN (~$31) — Q4 2026 $FNWD — Finward Bancorp → First Financial — 1.35 FFBC all-stock — Q4 2026 $PERF — Perfect Corp. → founder take-private — $2.00 cash (81% of votes locked) — Q4 2026 Highlights worth your attention: $ARX joins by reader request — and it’s the biggest addition of the week: Shell’s plan of arrangement for Canada’s largest Montney producer is already 99.5% shareholder-approved with Competition Act, CTA and HSR cleared, leaving court formalities and Investment Canada review — a timing trade that pays C$0.21 quarterly dividends while you wait (note: the package floats with Shell’s LSE price and GBP/CAD). $LXP suspends its common dividend during pendency (real negative carry) but carries a 40-day go-shop through Aug 28 — free optionality. $DSGR and $PERF are controlled take-privates with votes effectively assured — the spread is pure timing. $BLFS’s floating package has already slipped below the $31 headline as RGEN sold off — the tracker computes the live blend daily. And one deal we evaluated and didn’t add: Tempus/Personalis — Tempus stock is already trading below the $46.00 floor that hands Personalis a walk-away right at closing. Until that resolves or terms are amended, the posted spread isn’t a real arb, and we’d rather show you 72 deals we trust than 73 we don’t.
New on ArbLens: “What’s Changed”
Every deal page now answers the question you actually have. When a deal moves — a court stipulation, a tender count, a spread blowout — the first thing you want isn’t the full thesis re-read; it’s what’s different since I last looked. The ArbLens Analysis on every deal now leads with a dated What’s Changed log capturing exactly that: the development, the date, and what it does to the setup. This week’s WBD entry, for instance, records the stipulation, the canceled hearing, and the ticking-fee math in four sentences — then the catalyst list and risk/reward rationale below it are refreshed to match. Alongside it, some housekeeping you’ll notice: all ten new deals shipped with full spread history from announcement day, and we cleaned the charts so day-one always means post-announcement — no more phantom 30% “spreads” from pre-news closes distorting the y-axis. Same tracker, sharper memory.
Binary Events on the Calendar
July 27 (Mon) — triple-header. $NSC’s full STB supplement is due — an accepted record starts the 12-month evidentiary clock. $LPRO’s tender expires at midnight. And $AVNS’s merger agreement says closing “no later than July 27” — expect a completion notice.
July 29 (Wed) — $AAUC outside date. The 50% binary: clearance, extension to Sept 29, or termination rights. Also: $LXP’s Q2 results.
July 31 (Fri) — $WBD joint trial-scheduling statements. The first read on whether spring 2027 is realistic.
Late July — $IMXI: Western Union Q2 earnings. Deal-appetite tone matters more than the numbers.
Aug 5 — $AXTA dual votes · Aug 7 — $WBD UK CMA Phase 1 report · Aug 10 — $IMXI auto-extension trigger · Aug 17 — $RAMP vote · Aug 28 — $LXP go-shop expires.
Top 6 by Spread — July 24, 2026
Ticker
Deal
Spread
Key Risk
$AAUC
Zijin / Allied Gold
49.9%
NDRC the sole gate; outside date Wednesday; possible Sept 29 extension
$ZIM
Hapag-Lloyd / ZIM
40.7%
PM opposition + Golden Share threat; distress pricing, not conventional arb
$IMXI
Western Union / Intermex
22.8%
NYDFS sole gate; NYC politics in the mix; WU’s walk-away option the real risk
$WBD
Paramount Skydance / WBD
20.3%
Merits trial (~April 2027) now the gate; ticking fee from Sept 30; June 1, 2027 expiry
$IRDM
Rocket Lab / Iridium
17.8%
RKLB below the $67.50 collar floor intraweek; ratio freezes at 0.40 beneath it; mid-2027
$GSAT
Amazon / Globalstar
14.0%
Long-dated multi-jurisdiction review into 2027; timeline compensation, not break risk
Biggest Spread Changes — Week of July 17–24
Ticker
Jul 17
Jul 24
Change
Why
$GNK
11.2%
1.0%
−10.2pp ▼
Market priced a negotiated endgame near the indicative value as the tender expired Friday
$WBD
15.4%
20.3%
+4.9pp ▲
Friday’s stipulation: no closing until a merits ruling or June 1, 2027 — duration repriced
$IMXI
19.2%
22.8%
+3.6pp ▲
NYC political noise around NYDFS; approval facts unchanged at 51 of 52
$IRDM
15.6%
17.8%
+2.2pp ▲
RKLB traded through the $67.50 collar floor — the conditional exposure is now live
$AAUC
51.4%
49.9%
−1.5pp ▼
Fractional drift into Wednesday’s outside date — noise, not information
Top 6 by Risk / Reward — Updated July 24
#
Ticker
Why
Spread
#1
$AAUC
The binary resolves Wednesday. ~50% prices near-coin-flip odds on a deal where every non-PRC approval is done and an extension mechanism reportedly exists. Extraordinary if clearance converts; 30–35% down on a hard break. Risk-tolerant capital only — and only until Wednesday.
49.9%
#2
$WBD
Held at #2 with a changed profile: same 20% spread, new spring-2027 window. ~22–25% annualized, plus 25¢/share/quarter ticking fee from Sept 30 and a $7B break-fee backstop. Now a merits-trial binary that pays you to wait. Trial scheduling July 31.
20.3%
#3
$IMXI
Promoted: the spread doubled while the facts didn’t. 51 of 52 approvals, NYDFS the sole gate, both parties reaffirmed in June. The widening is political noise — high reward if NYDFS clears, genuine elevated risk on WU’s options. Sized accordingly.
22.8%
#4
$NSC
Full supplement due Monday — an accepted record starts the 12-month evidentiary clock. ~13% over ~12 months with a $2.5B reverse fee. The review is visibly moving.
13.0%
#5
$GSAT
$90 from Amazon — no vote risk, no financing risk, FCC spectrum rights reaffirmed. The 14% is pure timeline compensation on one of the cleanest long-duration spreads on the board.
14.0%
#6
$BHF
Re-enters, replacing GNK: all-cash $70, shareholders approved in February, no antitrust issue. The ~11% to year-end is a timing premium on multi-state insurance approvals — the closest thing to a risk-free double-digit spread for patient capital.
10.7%
Ranking notes: two changes this week. $GNK exits — at a 1% spread with no signed agreement, it’s a contested-situation bet, not risk/reward; it lives on the Contested tab now. $BHF re-enters at #6 as the highest-certainty name in the tracker. $IMXI moves up to #3 on the logic that a doubled spread against unchanged facts is a better entry, not a worse one — read the full rationale before agreeing. And $WBD holding #2 is a judgment call worth stating plainly: 20% over ten months with a ticking-fee kicker still beats most of the board annualized, but it’s now a litigation binary, and if that duration doesn’t fit your book, $NSC and $GSAT below it are the same patience trade with less courtroom risk. $ZIM stays excluded — 41% against a Prime Minister’s “never” is distressed optionality, not risk/reward.
Deals Removed This Week
$NUVL — Nuvalent → GSK — $124.00/share tender, 91.3% in — CLOSED July 15 $NSA — National Storage Affiliates → Public Storage — all-stock — CLOSED
If you find ArbLens useful, consider sharing it with at least one person who might benefit — a fellow investor, analyst, or anyone who follows M&A. It’s free, and word of mouth is how this community grows. Help us find the next 200. arblens.com
Real-time deal alerts, spread movements, and analysis as they happen — follow @ArbLens between issues.
Get weekly merger arb insights delivered to your inbox — spreads, regulatory updates, and what to watch next.
For informational purposes only. Nothing here constitutes investment advice. Merger arbitrage involves significant risk including deal failure and loss of capital. Data sourced from public filings and third-party sources. Spreads shown are as of July 24, 2026 and update nightly on arblens.com.